References
- Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014:124;483–92.
- Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012;24:53–9.
- Nagatsuka H, Han PP, Taguchi K, Tsujigiwa H, Gunduz M, Fukunaga J, et al. Erdheim-Chester disease in a child presenting with multiple jaw lesions. J Oral Pathol Med 2005;34:420–2.
- Petrikowski CG, McGaw WT. Erdheim-Chester disease of the jaws: literature review and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90: 389–98.
- Valdez IH, Katz RW, Travis WD. Premature alveolar bone loss in Erdheim-Chester disease. Oral Surg Oral Med Oral Pathol 1990;70:294–6.
- Matsui K, Nagata Y, Hiraoka M. Radiotherapy for Erdheim-Chester disease. Int J Clin Oncol 2007;12:238–41.
- Brahim JS, Guckes AD, Rudy SF. Implant rehabilitation in Erdheim-Chester disease: a clinical report. J Prosthet Dent 1992;68:399–401.
- Adam Z, Koukalova R, Sprlakova A, Rehak Z, Cervinek L, Szturz P, et al.[Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review]. Vnitrni lekarstvi 2011;57:576–89.
- Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010;116:4070–6.
- Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013;121:1495–500.
- Arnaud L, Hervier B, Neel A, Hamidou MA, Kahn JE, Wechsler B, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:2778–82.
- Mossetti G, Rendina D, Numis FG, Somma P, Postiglione L, Nunziata V. Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease. Clin Exp Rheumatol 2003;21:232–6.
- Miller RC, Villa S, Kamer S, Pasquier D, Poortmans P, Micke O, et al. Palliative treatment of Erdheim-Chester disease with radiotherapy: a Rare Cancer Network study. Radiother Oncol 2006;80:323–6.
- Abrahim JS, Guckes AD, Rudy SF. Implant rehabilitation in Erdheim-Chester disease: a clinical report. J Prosthet Dent 1992;68:399–401.